Fecal Microbiota Transplantation Shows Promise for First-Line Primary C Diff Treatment (HCPLive)

A new Phase 3 trial from Norway suggests fecal microbiota transplantation (FMT) may be noninferior to vancomycin for first-episode Clostridioides difficile infection (CDI). Conducted across 20 hospitals, the trial showed a 66.7% cure rate with FMT vs. 61.2% with vancomycin, without increased adverse events. While still controversial in the U.S., this study signals FMT’s growing therapeutic credibility. Is this the beginning of a shift in first-line CDI care?